Revance Therapeutics Inc (NASDAQ: RVNC) on Friday, plunged -3.05% from the previous trading day, before settling in for the closing price of $3.94. Within the past 52 weeks, RVNC’s price has moved between $2.30 and $9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 815.27% over the past five years. The company achieved an average annual earnings per share of 39.35%. With a float of $95.70 million, this company’s outstanding shares have now reached $104.90 million.
Let’s look at the performance matrix of the company that is accounted for 597 employees. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Revance Therapeutics Inc is 8.77%, while institutional ownership is 80.34%. The most recent insider transaction that took place on Nov 18 ’24, was worth 16,296. In this transaction CMO & Global Therapeutics Lead of this company sold 3,908 shares at a rate of $4.17, taking the stock ownership to the 104,945 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Commercial Officer sold 2,392 for $3.80, making the entire transaction worth $9,096. This insider now owns 114,864 shares in total.
Revance Therapeutics Inc (RVNC) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Revance Therapeutics Inc (RVNC) is currently performing well based on its current performance indicators. A quick ratio of 3.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Revance Therapeutics Inc (NASDAQ: RVNC) saw its 5-day average volume 1.43 million, a negative change from its year-to-date volume of 2.7 million. As of the previous 9 days, the stock’s Stochastic %D was 64.65%. Additionally, its Average True Range was 0.32.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 27.34%, which indicates a significant decrease from 40.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.53% in the past 14 days, which was lower than the 145.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.81, while its 200-day Moving Average is $4.52. Nevertheless, the first resistance level for the watch stands at $3.92 in the near term. At $4.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.11. If the price goes on to break the first support level at $3.74, it is likely to go to the next support level at $3.66. The third support level lies at $3.56 if the price breaches the second support level.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
Market capitalization of the company is 388.53 million based on 104,902K outstanding shares. Right now, sales total 234,040 K and income totals -323,990 K. The company made 59,880 K in profit during its latest quarter, and -38,120 K in sales during its previous quarter.
